Despite failure at drug trials, stock still ranked "strong buy" by TipRank's 60th best rated analyst and others. May be a an opportunity to buy Call LEAP
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
